Patología Intestinal S 21 Nuev os bi ológic os en EII - C. Figueroa C. Physicochemical characterization of Remsima®. MAbs 2014; 6: 1163-77. 15.- Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013; 72: 1605-12. 16.- Yoo DH, Racewicz A, Brzezicki J, Yatsyshyn R, Arteaga ET, Baranauskaite A, et al. OP0068 A Phase 3 randomised controlled trial to compare CT-P13 with infliximab in patients with active rheumatoid arthritis: 54 week results from the PLANETRA study. Arthritis Res Ther 2016; 18: 82. 17.- Ben-Horin S, Yavzori M, Benhar I, Fudim E, Picard O, Ungar B, et al. Crossimmunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima. J Crohn’s Colitis 2013; 7: 586- 9. 18.- Park SH, Kim YH, Lee JH, Kwon HJ, Lee SH, Park DI, et al. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Rev Gastroenterol Hepatol 2015; 9: 35-44. 19.- Gecse KB, Lovász BD, Farkas K, Banai J, Bene L, Gasztonyi B, et al. Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort. J Crohn’s Colitis 2016; 10: 133-40. 20.- Jahnsen J, Detlie TE, Vatn S, Ricanek P. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study. Expert Rev Gastroenterol Hepatol 2015; 9 Suppl 1: 45-52. 21.- Danese S, Gomollon F, Michetti P. EMA response to ECCO position statement on biosimilars. J Crohn’s Colitis 2014; 8: 259. 22.- Jahnsen J. Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients. Ther Adv Gastroenterol 2016; 9: 322-9. 23.- Hutas G1. Golimumab, a fully human monoclonal antibody against TNFalpha. Curr Opin Mol Ther 2008; 10: 393-406. 24.- Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146: 96-109. 25.- Reinisch W, Gibson P, Sandborn WJ, Feagan BG, Marano C, Strauss R, et al. Long-term safety and efficacy of golimumab in patients with moderately to severely active ulcerative colitis: Results from the PURSUIT-SC Maintenance study extensión.(Oral presentations) J Crohn’s Colitis. 2014; Supp1: S6-S7. 26.- Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis.N Engl J Med 2013; 369: 699-710. 27.- Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2013; 369: 711-21. 28.- Hanauer S, Rutgeerts P, Xu J, Rubin DT, Smyth M, Abhyankar B. Longterm efficacy of vedolizumab therapy for Crohn’s disease. United European Gastroenterol J. 2014; 2 (Suppl 1): A66. 29.- Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373: 633-40. 30.- Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-tosevere Crohn’s disease. Gastroenterology 2008; 135: 1130-41. 31.- Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med 2012; 367: 1519-28. 32.- Vermeire S, O’Byrne S, Keir M, Williams M, Lu TT, Mansfield JC, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet 2014; 384: 309-18. 33.- Harris MS, Hartman D, Lemos BR, Erlich EC, Spence S, Kennedy S, et al. AVX-470, an orally delivered antitumour necrosis factor antibody for treatment of active ulcerative colitis: results of a first-in-human trial. J Crohn’s Colitis 2016; 10: 631-40. 34.- Chaparro M, Gisbert JP. New molecules in the treatment of inflammatory bowel disease. Gastroenterol Hepatol 2016; 39: 411-23. Gastroenterol. latinoam 2016; Vol 27, S upl Nº 1: S 14-S 21
Gastro_3
To see the actual publication please follow the link above